48 results about "Strong binding" patented technology

The application provides a preparation method of a functionalized phage probe and application of the functionalized phage probe in detection of escherichia coli. The functionalized phage is a recombinant phage (M13KO7@SaBP) in which streptavidin binding peptide (SaBP) is fused and expressed at the N terminal of the main capsid protein P8 protein of M13K07 phage. In the application, the gene encoding SaBP (MDVEAWLGAR) is inserted into the N terminal of the P8 protein gene of M13K07 phage by site-directed mutagenesis to prepare M13K07@SaBP. The stable signal amplification is realized by using the abundant P8 protein (about 2700) of M13 phage and the super strong binding force of biotin-streptavidin, the interference of food sample matrix is reduced by combining the magnetic separation technology, and a detection method of escherichia coli with high sensitivity and small sample matrix interference is constructed.

The invention discloses a hybridoma cell strain secreting an anti-CD4 antibody, the antibody and application of the hybridoma cell strain in detection of CD4 of cattle and sheep, and belongs to the technical field of biology. The hybridoma cell strain is 3F9 and is preserved in the China Center for Type Culture Collection on June 13, 2025, and the preservation number is CCTCC (China Center for Type Culture Collection) NO: C2025183. The anti-CD4 antibody 3F9 secreted by the hybridoma cell strain provided by the invention has the advantages of high titer and strong binding affinity with natural antigens, and can be used for detecting natural cattle CD4 and sheep CD4 molecules.

This invention belongs to the field of antigen recognition technology, specifically relating to an antibody or its antigen-binding fragment that targets and recognizes mCD155, and its applications. The antibody targeting and recognizing mCD155 includes sequences as shown in SEQ ID NO:8 and SEQ ID NO:16 or as shown in SEQ ID NO:24 and SEQ ID NO:32; it has a strong binding affinity to the mCD155-his protein; and CAR-T cells constructed based on this antibody exhibit excellent killing (apoptotic) activity against mCD155-mediated tumors.

Provided in the present invention are a solid form of a cyclic amine derivative, a preparation method therefor, and a pharmaceutical composition, specifically relating to a solid form of a compound of formula I or a salt thereof, a preparation method therefor, and a pharmaceutical composition. The compound of formula I or the salt thereof provided by the present invention has strong binding ability to apo(a) and high stability, and can be better used in clinical practice.

The utility model discloses a multi-layer graphene heat-conducting sheet with strong binding force and rebound resilience, which comprises a plurality of graphene films which are punched by a laser and irradiated by an ultraviolet lamp for 1-2 minutes; coating the surface of the first graphene film with a first silica gel layer; placing a second graphene film on the first silica gel layer; enabling a part of the first silica gel layer to permeate into the holes of the first graphene film and the second graphene film; repeating the stacking to form a transverse graphene film and silica gel composite material block; cutting along the direction of the stacking thickness to form a plurality of stacked slices; the upper end face and the lower end face are subjected to degumming operation, graphene fiber filling operation is carried out after a hollow part is formed, all the graphene films can be connected with one another, and the multi-layer graphene heat-conducting sheet is high in binding force and rebound resilience. Therefore, the graphene has good bonding performance, can bear high compression rate without cracking, and fundamentally solves the cracking problem of the conventional graphene heat-conducting sheet.

This invention belongs to the field of biotechnology, providing a mouse anti-human ELL2 monoclonal antibody, its preparation method, and its applications. This invention successfully obtained a 2E1 anti-human ELL2 monoclonal antibody and established a hybridoma cell line capable of stably producing this antibody. The binding affinity (KD) of the obtained 2E1 monoclonal antibody to human ELL2 protein reached the picomolar level (approximately 10^-3 kDa). ‑12 The antibody (M) exhibits extremely strong binding ability. Cross-reactivity tests confirmed that it binds only to human ELL2, and shows no binding signal with highly homologous human ELL1, ELL3, and mouse ELL2, thus completely solving the specificity problem of existing technologies.

A metal-chelating resin includes (a) a compound represented by Formula (I):or a stereoisomeric form thereof or a salt thereof, wherein R1, R2, R3, R4, Ra, Rb, Rc and Rd are as defined herein; and (b) an organic polymer resin having at least one complementary reactive functional group covalently linked with at least one linking group of the compound represented by Formula (I).

The application discloses an egg yolk antibody against Nocardiosis and a preparation method and application thereof, and relates to the technical field of biological medicines. A light chain sequence of the egg yolk antibody comprises a sequence shown in SEQ ID NO. 1, and a heavy chain sequence comprises a sequence shown in SEQ ID NO. 2. The application expands culture of pathogenic bacteria Nocardia, prepares an inactivated bacterin vaccine, and immunizes hens, so that the hens produce egg yolk antibodies against Nocardia through an immune response. After immunization, the application collects eggs, extracts the egg yolk antibodies against Nocardiosis from egg yolk by using a water dilution method. It is verified that the egg yolk antibodies have a strong binding capacity with Nocardia, can effectively inhibit Nocardia, and the titer can reach 1:64000 at the highest.

The application relates to a G-quadruplex RNA fluorescent ligand and a preparation method and application thereof, a structure formula of the G-quadruplex RNA fluorescent ligand is shown in the following formula: the compound can be specifically targeted and can be subjected to fluorescent imaging in a solution system and a cell system, a high-throughput fluorescent screening method is established in the solution and the cell system, and an organic small-molecule compound with strong binding capacity to G-quadruplex RNA can be effectively identified and screened from a small-molecule drug library; the screening result of the method is high in accuracy, the affinity and biological activity of a candidate compound can be quickly determined by evaluating the change of a fluorescent signal, and therefore the research and development process of an antitumor drug is accelerated; and the application belongs to the field of biological medicines.

The invention discloses a decentralized identity strong binding and security recovery method. The method comprises the following steps: S1, deploying an intelligent contract on a block chain network; s2, a user generates a main public and private key pair through a smart contract, the smart contract allocates a unique decentralized identifier to a main public key, sets the main public key to be in an unverified state, and stores an association relationship between the decentralized identifier and the main public key; and S3, for the decentralized identifier in the unverified state, the user submits a binding assertion to the smart contract for validity verification, and after verification is passed, the decentralized identifier is converted into a verified state and granted with authority. The invention also discloses a decentralized identity strong binding and security recovery system. According to the method, the intelligent contract can realize operation of corresponding functions, intervention of a centralized mechanism is not needed in the whole process, the autonomous controllable characteristic of decentralized identity is reserved, and unification of safety, credibility and usability is realized through multi-party authoritative endorsement and a strict verification mechanism.

The application provides an anti-IGFBP5 nanobody and a preparation method, application and product thereof, and belongs to the technical field of biotechnology.The anti-IGFBP5 nanobody provided by the application contains a CDR region shown in SEQ ID NO:1-3, or one or more amino acid sequences with a sequence similarity of at least 90% with SEQ ID NO.1-3 respectively, the anti-IGFBP5 nanobody prepared by the application has strong binding capacity and can inhibit tumor cell growth.

The invention discloses a conjugate of phosphorylated Tau protein and magnetic beads as well as a preparation method and a kit of the conjugate, and relates to the technical field of immunoassay. The modified magnetic beads modified with azide groups and the modified anti-phosphorylated Tau protein antibody modified with DBCO groups are efficiently and directionally coupled in a click chemistry mode, and compared with a traditional physical adsorption or non-specific chemical coupling method, the method has the advantages of being high in coupling efficiency, high in binding stability, high in antibody activity retention rate and the like; compared with the prior art, the magnetic bead provided by the invention has the advantages that the capture efficiency and specificity of the magnetic bead on low-abundance p-Tau in blood can be obviously improved, the lower detection limit is as low as 0.3 pg / mL or below, excellent accuracy is shown in early AD diagnosis, subtle changes of p-Tau in the blood of an early AD patient can be accurately identified, and a reliable tool is provided for early screening, disease course monitoring and intervention effect evaluation of AD.

The present invention provides a bispecific antibody and a use thereof. The bispecific antibody comprises a first protein functional zone and a second protein functional zone. TIM-3 full-length antibody of targeting TIM-3 corresponding to the targeting TIM-3 in the first protein functional zone has a low binding activity with Macaca TIM-3, has strong binding activity with Marmoset and human TIM-3, and can activate the killing effect of a human NK cell on the tumor cell. The bispecific antibody reserves the activity of a single TIM-3 antibody of activating PBMC (NK) to kill the tumor cell while reserving the original activity of the other protein functional zone, and can achieve the same activity of being combined with two molecules or better activate the activity of a T lymphocyte.

The utility model relates to the technical field of auxiliary treatment of knee osteoarthritis, and discloses a brace for auxiliary treatment of knee osteoarthritis, which comprises a knee joint protector and a rotating frame, and the left end and the right end of the knee joint protector are fixedly connected with fixing snap rings. By arranging the two binding belts, after a user wears the leg, the binding belts are matched to bind the position of the leg, and when the length positions of the legs of the user are different, the binding belts are pulled to drive the extending sliding rod to extend and slide in the fixing sleeve, so that the leg length position of the user is adjusted. The length of the device can be conveniently adjusted according to the leg length of a user, when the user wears the device for use, rehabilitation training of the user is easily affected due to the fact that the constraint feeling is high when the user just starts to wear the device, movement is inconvenient, bumping is generated, and the device is worthy of popularization and application. And after the protective base plate is mounted in the fixed clamping ring and the positioning groove, the phenomenon that the knees collide with table corners or objects with edges and corners is reduced.

The invention relates to a security system and method for strongly binding a program and a hardware identifier, and belongs to the technical field of software protection and equipment authentication. According to the invention, an'authorization certificate 'uniquely bound with specific equipment is generated through a scheme of'encrypting a hardware identifier by a secret key derived from the hardware identifier'. The credential cannot be correctly decrypted and verified on any other hardware. When a protected program and an authorization certificate thereof are completely copied to another non-authorized device, due to different local hardware identifications of a new device, a correct decryption key cannot be generated when a program verification preamble module of the new device performs self-inspection, so that decryption fails and program operation is forcibly stopped, and therefore, pirate behaviors are effectively prevented.

The invention belongs to the technical field of biology, and discloses an anti-human AXL antibody, a gene and application of the anti-human AXL antibody, and amino acid sequences of a heavy chain variable region and a light chain variable region of the anti-human AXL antibody are respectively shown as SEQ ID NO.23-34. The anti-human AXL antibodies in some examples have the binding capacity EC50 value smaller than 2 nM for AXL antigens and have no binding capacity for irrelevant antigens Her2 and BSA, and it is indicated that the screened targeted AXL antibodies have high specificity and high binding activity. Different AXL / CD3 bispecific antibodies prepared on the basis of the anti-human AXL antibody have relatively strong killing ability (IC50: 0.1-0.5 nM) on AXL positive MDA-MB-231 cells, and have very low killing ability on AXL negative SKBR3 cells, so that off-target toxicity of the different AXL / CD3 antibodies is avoided, and the application of the different AXL / CD3 bispecific antibodies is further widened.

The application discloses an antibody against human CD180 and application thereof. The antibody against human CD180 A24C9 and C12F11 provided by the application has strong affinity with human CD180 protein, and the Kd values are 0.4748 nM and 78.19 nM respectively; meanwhile, the antibody has strong binding specificity and can specifically recognize human CD180 positive acute myeloid leukemia (AML) cell lines (OCI-AML2, MV4-11, THP1) and human CD180 positive B cell lymphoma cell lines (Daudi, BJAB, Nalm6); and the antibody has no cross reaction with various human CD180 negative cell lines (K562, NB4, Kasumi1, TF1, NK92, Jurkat, SupT1 and MM1S). The antibody can be used for detecting expression of human CD180 protein, and can be used in immunotherapy alone or in combination with other methods, and has diagnostic and therapeutic values in tumors, autoimmune diseases, graft-versus-host diseases and inflammatory diseases.

This invention discloses a strongly interfacially bonded multimetal hydroxide catalyst electrode, its preparation method, and its application, belonging to the technical field of alkaline water electrolysis hydrogen production catalyst preparation. First, a metal substrate is pretreated. Then, using the metal substrate as the working electrode and a platinum sheet as the counter electrode, deposition is performed using a dual-potential step chronoamperometric method. After deposition, a multimetal hydroxide catalyst electrode is obtained. This invention utilizes the aforementioned strongly interfacially bonded multimetal hydroxide catalyst electrode, its preparation method, and its application. The resulting multimetal hydroxide catalyst electrode exhibits high uniformity and strong bonding with the substrate, and can operate stably under the high temperature, high alkalinity, and high current density conditions of industrial alkaline water electrolysis hydrogen production.

The invention provides a protein editing system and application thereof, and belongs to the technical field of biology, the protein editing system is successfully constructed on the basis of functional research of RSV M2-1 protein, by utilizing the characteristic that recruited PARN protein is reserved by mutant protein K92A and has an mRNA tail degradation function, and by combining the strong combining capacity of a lambda N-BoxB system, the protein editing system can be used for editing the protein. The system comprises effector plasmids and targeting plasmids, the targeting plasmids aiming at target proteins are edibly constructed, and the targeting plasmids and the effector plasmids are matched to be introduced into host cells, so that the expression of specific target proteins in the cells is remarkably knocked down. The protein editing system can be developed into a product for protein editing, has been successfully applied to knock-down expression of various proteins and pathogens, can avoid irreversible damage of a gene level caused by gene editing, provides a new solution thought for rapid application of gene knock-down expression, and has a wide application prospect.

The present invention relates to novel albumin binding constructs that enhance the pharmacokinetic performance of therapeutic peptides and proteins, extend their half-life and reduce the frequency of administration. The core peptide DICLPRWGCLW (SEQ ID NO: 1) is covalently linked to a hydrophilic and flexible glycine-serine (Gly-Ser) linker of the formula (ggs) xg, wherein x is from 3 to 8 units. The linkers provide a strong binding force (dissociation constant lt; 20 nanomoles) to albumin. Some constructs have a GGSGGSGGSGGRLIEDICLPRGCLWEDD (SEQ ID NO: 4) peptide, allowing fusion of active proteins, such as Klotho, maintaining biological activity, and utilizing the long half-life of albumin. In some embodiments, constructs are produced using cellular expression systems (CHO cells, HEK293 cells, transgenic insect cells) to ensure scalability. Upon administration, these constructs exhibit an extended half-life up to at least 90% of the half-life of native albumin. The novel Klotho constructs using the novel albumin conjugates show a FGF23 binding dissociation constant of from 15 to 30 nanomoles, substantially the same as that of natural Klotho. These constructs are designed to minimize antigenicity, thereby enhancing drug delivery effectiveness and improving patient prognosis.

The invention discloses a strong binding authentication method and device for a user and equipment and a terminal. The method comprises the following steps: acquiring input data of a to-be-authenticated user on target equipment; the input data comprises behavior characteristics of the to-be-authenticated user and hardware characteristics of the target equipment; preprocessing the input data to obtain preprocessed data; performing feature extraction on the preprocessed data through a pre-trained target contrast learning network to obtain a to-be-authenticated high-dimensional feature; and judging the to-be-authenticated high-dimensional feature according to a preset judgment algorithm to obtain an authentication judgment result. According to the invention, the behavior characteristics of the user and the hardware characteristics of the equipment are fused, so that the security and uniqueness of identity authentication are improved. Meanwhile, feature extraction is optimized by using a comparative learning network, so that better feature space separation is realized, the influence of environmental factors is reduced, and the robustness and stability of identity authentication are ensured.

The invention belongs to the technical field of biological medicines, and particularly relates to a human and mouse serum albumin cross reaction nano antibody derived from a fully synthetic antibody library. Nine nano antibodies capable of being specifically combined with human serum albumin are found through nano antibody synthesis library phage screening. A cross-reactive ELISA experiment is carried out on the related nano antibody clones, the four antibody clones are found to have specific binding to MSA, and Nb-HSA-5 shows relatively strong binding force to MSA; the Nb-HSA-4 does not react with the MSA and the BSA at all under the condition that the Nb-HSA-4 is strongly combined with the HSA, so that the combination of the Nb-HSA-4 and the HSA has strong specificity. The anti-HSA nano antibody can be used for preparing an HSA diagnostic kit, a targeted therapeutic drug, a carrier conjugate for prolonging the plasma half-life period of the drug and the like, and a new tool is provided for diagnosis and treatment of various related diseases.

This invention relates to medical-grade polyetheretherketone (PEEK) composite materials, their preparation method, and human bone implants, belonging to the field of medical materials technology. It addresses the limitations of existing human bone implants in promoting bone tissue regeneration and repair, as well as their poor antibacterial properties. The composite material comprises 1000 parts PEEK powder, 100-500 parts of HAP-modified ZIF-8 composite material after sizing, 1-3 parts of silane coupling agent, and 2-5 parts of calcium stearate. The sizing-treated HAP-modified ZIF-8 composite material is obtained by reacting HAP, methylimidazole, and anhydrous zinc nitrate in a DMF solution of polyetherimide; wherein HAP comprises 3-21 parts, methylimidazole 100-350 parts, and anhydrous zinc nitrate 120-380 parts. This invention can be used in human bone implants, possessing antibacterial properties, strong binding ability to bone cells and tissues, and the ability to promote the regeneration and repair of bone cells and tissues, showing broad application prospects in the medical field.

The invention relates to a polypropylene insulating material for bipolar coagulation forceps and a preparation method of the polypropylene insulating material, and belongs to the technical field of high polymer materials. A rutile phase solid solution formed by doping europium ions and niobium ions in the modified ceramic powder with titanium dioxide provides a deep trap and can capture free carriers in the material, nano-zinc oxide provides a shallow trap and assists ordered migration of the carriers, and the nano-zinc oxide and the shallow trap form a double-trap synergistic effect. Free carriers with high energy are preferentially captured by a deep trap of europium ion and niobium ion doped titanium dioxide, the carriers can be fixed at lattice defects by the strong binding force of the deep trap and prevented from forming a conductive path, part of low-energy carriers can be captured by a shallow trap and prevented from gathering towards a deep trap area, and space charge accumulation is reduced.

The application discloses an anti-FDA0128 antibody and application thereof. The amino acid sequences of a heavy chain variable region and a light chain variable region of the FDA0128 are shown in SEQ ID NO: 3 and 4 respectively; the anti-FDA0128 antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region comprises HCDR1 of an amino acid sequence shown in SEQ ID NO: 17 or 22, HCDR2 of an amino acid sequence shown in SEQ ID NO: 18 or 23 and HCDR3 of an amino acid sequence shown in SEQ ID NO: 19 or 24; and the light chain variable region comprises LCDR1 of an amino acid sequence shown in SEQ ID NO: 20 or 25, LCDR2 of an amino acid sequence shown in YAY or LAS and LCDR3 of an amino acid sequence shown in SEQ ID NO: 21 or 26. The anti-FDA0128 antibody of the application has strong binding force with the FDA0128, and can realize rapid and accurate pharmacokinetic analysis on the FDA0128 antibody and the FDA0128 antibody conjugated drugs.

The present application relates to a kind of MDA5 antibody and its preparation method and application.The present application selects the human-derived monoclonal antibody of anti-MDA5, with high activity, good stability and strong binding specificity, provides new tool for the diagnosis, monitoring and treatment of dermatomyositis and its complications.

The invention discloses a self-healing zinc powder integrated negative electrode material and a preparation method thereof, the chemical composition expression of the material is Zn-xM-yP-zN, in the formula, x, y and z are respectively mass percentages of M, P and N, x is more than or equal to 5 and less than or equal to 15, y + z is more than or equal to 5 and less than or equal to 15, y is more than or equal to z, and the balance is Zn, M is an MBenes material, P is protein, and N is N-carboxyl anhydride; the material is obtained by mixing zinc powder subjected to acid treatment with a protein solution to prepare amyloid fiber composite zinc powder, then adding the amyloid fiber composite zinc powder into an MBenes solution, performing ultrasonic stirring, then dropwise adding an N-carboxyl anhydride solution containing a quaternary ammonium carboxylate initiator, and performing secondary ultrasonic stirring. The preparation method is simple, the process is easy to control, and the prepared material has the characteristics of self-healing, high mechanical strength, strong binding force, excellent cycling stability and the like, and can be widely applied to the fields of wearable equipment, electric automobiles and the like.

The invention belongs to the field of functional fabrics, and particularly relates to a bio-based fabric with antibacterial and toughening functions and a preparation method thereof.The bio-based fabric comprises a fabric with bio-based fibers as a main body and a microcapsule antibacterial system fixed to the fabric; the microcapsule antibacterial system is composed of a core body and a wall material, and the core body of the microcapsule is composed of a bio-enzyme cross-linked enzyme aggregate and a stabilizer; the microcapsule wall material contains a component which forms a firm interface with the fiber; according to the invention, through a dual stabilization mechanism of CLEAs structure stabilization and microcapsule barrier protection on enzyme, the problems that free enzyme on the fabric is poor in stability and easy to fall off are solved, and the antibacterial activity of the enzyme is maintained for a long time. On the other hand, the strong binding force of the microcapsules and the fabric can improve the self strength of the fabric and improve the breaking strength and tearing strength of the bio-based fabric, meanwhile, the antibacterial property of the enzyme can effectively inhibit erosion and breeding of microorganisms to the bio-based fabric, and finally the effects of keeping clothes fresh for a long time and prolonging the service life of the fabric are achieved.

The invention relates to a micro-nano system for peritoneal dialysis. The components of the micro-nano system comprise large-mass substances, such as macromolecules, polymers and tiny structures formed by specific substances. The large-mass substances have the advantage of high combining capacity with wastes / toxins in the dialysate. The micro-nano system is dissolved or suspended in the dialysate, and large-mass substances in the micro-nano system extract and enrich waste in the peritoneal dialysate during peritoneal dialysis, so that the capacity of the dialysate is enhanced.

This invention discloses a triazole compound, its preparation method, and its applications. The triazole compound is of formula I. The triazole compound provided by this invention exhibits strong binding activity to TEAD protein. After binding to TEAD protein, the compound significantly enhances the protein's thermal stability while inhibiting TEAD protein activity. It effectively disrupts the TEAD-YAP interaction and demonstrates strong anti-proliferative activity against the NCI-H226 cell line with abnormal Hippo pathway NF2 deficiency, thereby enabling the treatment of diseases related to abnormal TEAD protein regulation or Hippo pathway abnormalities.